Cargando…
CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Inactivating p53 mutations are the most abundant genetic alterations found in cancer. Here we show that CRISPR/Cas9-induced double-stranded DNA breaks enrich for cells deficient in p53 and in genes of a core CRISPR–p53 tumor suppressor interactome. Such enrichment could predispose to cancer developm...
Autores principales: | Jiang, Long, Ingelshed, Katrine, Shen, Yunbing, Boddul, Sanjaykumar V., Iyer, Vaishnavi Srinivasan, Kasza, Zsolt, Sedimbi, Saikiran, Lane, David P., Wermeling, Fredrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397613/ https://www.ncbi.nlm.nih.gov/pubmed/34750099 http://dx.doi.org/10.1158/0008-5472.CAN-21-1692 |
Ejemplares similares
-
Designing custom CRISPR libraries for hypothesis-driven drug target discovery
por: Iyer, Vaishnavi Srinivasan, et al.
Publicado: (2020) -
A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system
por: Shen, Yunbing, et al.
Publicado: (2021) -
A CRISPR-p53 interactome with potential implications for clinical CRISPR/Cas9 use
por: Jiang, Long, et al.
Publicado: (2022) -
Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
por: Sayed, Shady, et al.
Publicado: (2022) -
Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer
por: Zhao, Xiaoyu, et al.
Publicado: (2021)